文献速递脑血管病外科神经重症

抗血小板治疗预防高危破裂颅内动脉瘤弹簧圈栓塞围手术期血栓栓塞

Antiplatelet therapy for the prevention of peri-coiling thromboembolism in high-risk patients with ruptured intracranial aneurysms.
PubMed 文献 · J Neurosurg · 2017-01-06

该研究先回顾169例血管内治疗颅内动脉瘤患者的前瞻性登记,识别与围手术期血栓栓塞事件(TEE)相关的6项血管造影特征,再对79例具有高危特征(至少1项TEE相关血管造影特征)的破裂动脉瘤患者进行前后对照研究,评估选择性阿司匹林给药能否降低围手术期TEE且不增加出血并发症。结果显示阿司匹林使TEE从对照组53.8%降至阿司匹林组10.6%(p=0.001),校正后OR为0.16(95%CI 0.03-0.8),无重大全身出血并发症,未增加动脉瘤再出血、症状性颅内出血或EVD相关大出血风险(p=0.3),但阿司匹林组无症状性EVD相关小出血(<1 cm)增加(p=0.02)。作者认为高危破裂动脉瘤患者抗血小板治疗可显著降低围手术期TEE且不增加重大出血。

要点

  • 6项血管造影特征与围手术期TEE相关:宽瘤颈、弹簧圈或袢突出、载瘤动脉直径小、分支嵌入、术中血栓形成、颅内载瘤动脉粥样硬化。
  • 高危破裂动脉瘤患者中,阿司匹林组围手术期TEE发生率为10.6%,低于对照组的53.8%(p=0.001)。
  • 校正年龄、性别、心血管危险因素及宽瘤颈、动脉瘤≥10 mm后,阿司匹林与TEE降低独立相关(校正OR 0.16,95%CI 0.03-0.8)。

核心结论

  • 研究结果表明,对于具有高危特征的破裂动脉瘤患者,抗血小板治疗可显著降低围手术期TEE发生率,且不增加重大全身或颅内出血。

研究设计与样本

  • 回顾性分析169例血管内治疗颅内动脉瘤患者的前瞻性登记资料,识别与围手术期TEE相关的血管造影特征。
  • 随后对79例具有高危特征(至少1项TEE相关血管造影特征)的破裂动脉瘤患者进行前后对照研究,评估选择性阿司匹林给药的效果。

主要发现

  • 6项血管造影特征与围手术期TEE相关:宽瘤颈、弹簧圈或袢突出、载瘤动脉直径小、分支嵌入、术中血栓形成、颅内载瘤动脉粥样硬化。
  • 阿司匹林组围手术期TEE发生率为10.6%,对照组为53.8%(p=0.001)。
  • 校正年龄、性别、心血管危险因素(吸烟、糖尿病、高血压、血脂异常、冠心病)及其他大型研究中与TEE相关的因素(宽瘤颈、动脉瘤大小≥10 mm)后,阿司匹林与TEE降低仍显著相关,校正OR为0.16(95%CI 0.03-0.8)。
  • 无重大全身出血并发症;阿司匹林未增加动脉瘤再出血、症状性颅内出血或EVD相关大出血风险(p=0.3);但阿司匹林组无症状性EVD相关小出血(<1 cm)增加(p=0.02)。

关键数值与推荐

  • 高危破裂动脉瘤患者接受阿司匹林后围手术期TEE发生率为10.6%,未接受阿司匹林的对照组为53.8%(p=0.001)。
  • 校正年龄、性别、心血管危险因素、宽瘤颈及动脉瘤大小≥10 mm后,阿司匹林与TEE降低的校正OR为0.16(95%CI 0.03-0.8)。

临床怎么用

  • 对于具有高危血管造影特征的破裂颅内动脉瘤患者,围手术期选择性使用阿司匹林可能降低围手术期血栓栓塞事件风险,且不增加重大出血并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE The most frequent procedural complication of the endovascular treatment of intracranial aneurysms is a thromboembolic event (TEE); in a subset of patients, such events will cause permanent neurological disability. In patients with unruptured aneurysms, increasing evidence supports the use of periprocedural antiplatelet therapy to prevent TEEs. The object of this study was to evaluate whether patients with ruptured aneurysms and subarachnoid hemorrhage would also benefit from periprocedural antiplatelet therapy. METHODS The authors reviewed a prospective registry of 169 patients with endovascularly treated intracranial aneurysms to delineate angiographic features associated with periprocedural TEEs. They then performed a controlled before-and-after study in 79 patients with ruptured aneurysms who were deemed to be at high risk for TEEs (for example, patients with at least 1 angiographic feature associated with TEEs) to evaluate whether selective aspirin administration would reduce the rate of periprocedural thromboembolism without increasing major hemorrhagic complications. RESULTS Six angiographic features were associated with periprocedural TEEs in the study cohort: wide aneurysm neck, coil or loop protrusion, small parent artery diameter, an incorporated branch, intraprocedural thrombus formation, and intracranial parent vessel atherosclerosis. Aspirin administration to high-risk patients significantly decreased the rate of periprocedural TEEs, from 53.8% in the control group to 10.6% in the aspirin-treated group (p = 0.001). The reduction in TEEs in the aspirin-treated group continued to be statistically significant even when adjusted for age, sex, cardiovascular risk factors (smoking, diabetes, hypertension, dyslipidemia, coronary artery disease), and factors associated with TEEs in other large studies (wide aneurysm neck, aneurysm size ≥ 10 mm), with an adjusted OR of 0.16 (95% CI 0.03-0.8). There were no major systemic hemorrhagic complications, and aspirin did not increase the risk of aneurysm rebleeding, symptomatic intracranial hemorrhage, or major external ventricular drain (EVD)-associated hemorrhage (p = 0.3), though there was an increase in asymptomatic, minor (< 1 cm) EVD-associated hemorrhage in the aspirin-treated group (p = 0.02). CONCLUSIONS The study findings suggest that for ruptured aneurysm patients with high-risk features, antiplatelet therapy can significantly reduce the rate of periprocedural TEE without increasing major systemic or intracranial hemorrhages.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Edwards NJ, Jones WH, Sanzgiri A, et al. Antiplatelet therapy for the prevention of peri-coiling thromboembolism in high-risk patients with ruptured intracranial aneurysms. J Neurosurg. 2017. PMID: 28059659. doi:10.3171/2016.9.JNS161340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。